XPC Deficiency Activate Cisplatin‐Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1‐Mediated Ubiquitination of the p53 Protein
Advanced Science · 2026
DOI: 10.1002/advs.202517563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Baixiong Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cisplatin, Autophagy, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Muscle‐invasive bladder cancers (MIBC) are biologically heterogeneous and have widely variable conventional chemotherapy responses and clinical outcomes. This study demonstrates that XPC deficiency in bladder cancer cells can promote autophagy in response to the cisplatin‐mediated DNA damage response (DDR). This process is closely related to both the overexpression of KDM4A and the downregulation of PHRF1 induced by the overactivation of ATM phosphate. The overaccumulation of KDM4A can suppress PHRF1 expression and result in significant nuclear accumulation of the p53 protein. Notably, this study defines a new mechanism by which PHRF1 regulates p53 posttranslationally through the ubiquitin‐proteasome system. In XPC low expression cells, PHRF1 performs a more critical E3 ubiquitin ligase function than MDM2. Especially under conditions of cisplatin‐mediated DNA damage where MDM2 function is impaired, PHRF1 retains its functionality. In a mouse xenograft model, combining a KDM4 inhibitor with cisplatin results in superior antitumor effects compared with cisplatin alone. These findings provide new insights into the phenotypic plasticity of bladder cancer under drug resistance and highlight the potential of KDM4A inhibition and preservation of PHRF1 function in overcoming cisplatin resistance. Therefore, KDM4A or PHRF1 may be potential novel targets for the treatment of bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China.
- Department of Cell Biology, Army Medical University, Chongqing, 400038, China.
- Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41345, Sweden.
- Department of Surgery, Sahlgrenska University Hospital, Gothenburg, 41345, Sweden.
ORCID-Profile: Jin Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhao, B., Huang, Y., Shi, J., Zhou, X., Fagman, J. B., Wang, L., Liu, S., Wang, W., Liu, Y., Chen, Z., & Yang, J. (2026). XPC Deficiency Activate Cisplatin‐Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1‐Mediated Ubiquitination of the p53 Protein. Advanced Science. https://doi.org/10.1002/advs.202517563
Vancouver
Zhao B, Huang Y, Shi J, Zhou X, Fagman JB, Wang L, et al. XPC Deficiency Activate Cisplatin‐Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1‐Mediated Ubiquitination of the p53 Protein. Advanced Science. 2026. doi:10.1002/advs.202517563
BibTeX
@article{Zhao2026,
author = {Zhao, Baixiong and Huang, Yaqin and Shi, Jiazhong and Zhou, Xiaozhou and Fagman, Johan Bourghardt and Wang, Liwei and Liu, Sha and Wang, Wuxing and Liu, Yuting and Chen, Zhiwen and Yang, Jin},
title = {XPC Deficiency Activate Cisplatin‐Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1‐Mediated Ubiquitination of the p53 Protein},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202517563}
}
EUVIMED